Evidence map›Paper›PMID 41320782›Full record

ArticleJournal of biomedical science2025

The impact of single-nucleotide variants of hepatitis B virus and antiviral on liver cancer in gray zone patients.

Wei Teng, Ting-Tsung Chang, Chien-Wei Su, Jun-Hao Xu, Chiu-Chi Hsu, Yu-Cheng Chang, Wen-Chun Liu, Yu-Wei Chiou, Yu-Chuan Chang, Yuh-Jin Liang and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of biomedical science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Wei Teng *Institute of Clinical Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan, ROC.ORCID http://orcid.org/0000-0001-5663-1440
Ting-Tsung Chang *Department of Internal Medicine, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan, ROC.ORCID http://orcid.org/0000-0002-5073-2678
Chien-Wei SuDivision of General Medicine, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan, ROC.ORCID http://orcid.org/0000-0003-3889-7004
Jun-Hao XuInstitute of Clinical Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan, ROC.
Chiu-Chi HsuInstitute of Clinical Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan, ROC.
Yu-Cheng ChangInstitute of Clinical Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan, ROC.
Wen-Chun LiuDepartment of Nursing, National Tainan Junior College of Nursing, Tainan, Taiwan, ROC.ORCID http://orcid.org/0000-0001-9048-6363
Yu-Wei ChiouInstitute of Clinical Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan, ROC.
Yu-Chuan ChangInstitute of Clinical Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan, ROC.
Yuh-Jin LiangInstitute of Clinical Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan, ROC. yuh.jin.liang@gmail.com.ORCID http://orcid.org/0000-0003-3774-3329
Jaw-Ching WuInstitute of Clinical Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan, ROC. jcwu@vghtpe.gov.tw.ORCID http://orcid.org/0000-0001-9645-3044

Funding

Chang Gung Medical Foundation CMRPG3M1721，CMRPG3M1691Ministry of Education 112W31101Ministry of Education 113W031101Ministry of Education 114W031101Ministry of Health and Welfare 113-TDU-B-221-134007Ministry of Health and Welfare 114-TDU-B-221-144007Ministry of Health and Welfare MOHW112-TDU-B-221-124007National Science and Technology Council 110-2628-B-182A-008National Science and Technology Council 111-2811-B-A49A-040National Science and Technology Council 111-2923-B-A49-001National Science and Technology Council 112-2314-B-A49-001National Science and Technology Council 112-2314-B-A49-011National Science and Technology Council 112-2811-B-A49A-043National Science and Technology Council 113-2314-B-075 -052 -MY3National Science and Technology Council 113-2314-B-A49-005National Science and Technology Council 113-2314-B-A49-043National Science and Technology Council 113-2923-B-A49-001Taipei Veterans General Hospital V112C-057Taipei Veterans General Hospital V113C-070Taipei Veterans General Hospital V114C-102
6 · The paper itself

Abstract

objectivesThis study investigated the impact and related mechanisms of single-nucleotide variants (SNVs) in the HBV pre-S/S region on tumor development, and evaluated the role of antiviral therapy.

methodsA retrospective analysis was conducted in 104 patients of the gray zone. HCC-associated SNVs were analyzed in baseline samples.

resultsHCC occurred in 15 patients (14.4%) during the median follow-up period of 10.4 years. Genotype B HBV-infected HCC patients had more T53C, A273G, and A529G SNVs and genotype C HBV-infected HCC patients had more T53C, G633A, and A3120G SNVs than HCC-free groups. Antiviral therapy reduced the risk of HCC in patients with HCC-associated SNVs in the gray zone both genotype B or C. Ectopic expression of replication-competent HBV plasmids in Huh7 cells expressing HCC-associated SNVs resulted in greater impairment of mitochondrial dynamics, increased production of reactive oxygen species (ROS), decreased mitochondrial membrane potential, lower ATP production, higher basal calcium levels, and reduced calcium buffering capacity compared to controls or wild-type HBV-expressing cells.

conclusionsCHB patients in the gray zone remain at risk for HCC owing to both wild-type and HCC-associated HBV SNVs, especially the latter, inducing mitochondrial and metabolic dysfunctions. Antiviral therapy reduces the risk of HCC development in these patients.

Indexed as

Antiviral AgentsCarcinoma, HepatocellularHepatitis B, ChronicHepatitis B virusLiver NeoplasmsPolymorphism, Single NucleotideAdultAgedFemaleHumansMaleMiddle AgedRetrospective StudiesAntiviral AgentsAntiviral therapyMitochondrial dysfunctionPre-S/S regionSingle-nucleotide variantsTreatment guidelines

Identifiers

PMID41320782
PMCPMC12667080

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.